Main description:

The traditional approaches to treat various cancers include chemotherapy, radiation and/or hormonal therapy. While these therapies continue to be effective in large part, they are not selective and highly toxic. There have been encouraging results in alternative therapeutic approach called antibody-mediated anti-cancer therapy, which is less toxic, more selective, and can also reverse drug/radiation resistance. Monoclonal antibodies or mAbs can be used to destroy malignant tumor cells and prevent tumor growth by blocking specific cell receptors. mAbs can bind only to cancer cell-specific antigens and induce an immunological response against the target cancer cell. The book covers the common and unique features of mAbs agains various cancer, gives the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs, as well as discuss novel mAbs to overcome resistance.

Contents:

Part I. Immunotherapy with monoclonal antibodies (mAbs) against various cancers
1.Introduction and generation of chimeric and humanized mAbs
2. mAbs targeted against cancer cells and antibodies targeted against the tumor microenvironment
3. Antibodies directed against different major cancers: Effects when used alone or in combination with drugs
4. Mechanisms of antibodies-mediated responses, in vitro and in vivo
Part II. Development of resistance to mAbs
5. Molecular Pathways
6. Molecular Signatures
7. Identification of resistance targets for intervention
Part III. Agents that can sensitize resistant tumor cells to mAbs
8. Various chemicals that can sensitize resitant tumor cells
9. Other mAbs
10. Proteasome inhibitors
Part IV. Novel mAbs to overcome resistance
11. Divalent mAbs
12. Antibodies coupled to chemical inhibitors
13. Antibodies coupled to cytokines 14. Nanoparticles with mAbs